|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
|
US20050287153A1
(en)
*
|
2002-06-28 |
2005-12-29 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
EP2180054A1
(en)
*
|
1999-12-24 |
2010-04-28 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
US20060228364A1
(en)
*
|
1999-12-24 |
2006-10-12 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
US20040001827A1
(en)
*
|
2002-06-28 |
2004-01-01 |
Dennis Mark S. |
Serum albumin binding peptides for tumor targeting
|
|
KR20130056201A
(ko)
*
|
2000-05-19 |
2013-05-29 |
제넨테크, 인크. |
ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
|
|
AU2002355477B2
(en)
*
|
2001-08-03 |
2008-09-25 |
Medical Research Council |
Method of identifying a consensus sequence for intracellular antibodies
|
|
US7435797B2
(en)
*
|
2002-04-10 |
2008-10-14 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
|
AU2005214382B2
(en)
*
|
2004-02-19 |
2011-08-04 |
Genentech, Inc. |
CDR-repaired antibodies
|
|
KR20140032004A
(ko)
|
2004-07-22 |
2014-03-13 |
제넨테크, 인크. |
Ｈｅｒ２ 항체 조성물
|
|
WO2006042002A2
(en)
*
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
|
JP2008515889A
(ja)
*
|
2004-10-05 |
2008-05-15 |
ジェネンテック・インコーポレーテッド |
毒性の低下した治療剤
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
CA2592177A1
(en)
|
2005-01-21 |
2006-07-27 |
Genentech, Inc. |
Fixed dosing of her antibodies
|
|
EP1850874B1
(en)
|
2005-02-23 |
2013-10-16 |
Genentech, Inc. |
Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
AU2006338198B2
(en)
*
|
2005-12-02 |
2012-04-26 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
|
DK2056874T3
(da)
|
2006-08-21 |
2012-10-15 |
Hoffmann La Roche |
Tumorterapi med et anti-vegf-antistof
|
|
MX2009008981A
(es)
|
2007-03-02 |
2009-09-02 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her.
|
|
WO2008119566A2
(en)
*
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
|
RS53008B2
(sr)
†
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
US20090304590A1
(en)
*
|
2007-05-29 |
2009-12-10 |
Wyeth |
Therapeutic compositions and methods
|
|
US20090258005A1
(en)
*
|
2007-05-29 |
2009-10-15 |
Trubion Pharmaceuticals Inc. |
Therapeutic compositions and methods
|
|
EP2171090B1
(en)
|
2007-06-08 |
2013-04-03 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
AU2009308707A1
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
LIGHT targeting molecules and uses thereof
|
|
CN104447995A
(zh)
|
2009-03-20 |
2015-03-25 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
|
EP2435071A1
(en)
|
2009-05-29 |
2012-04-04 |
F. Hoffmann-La Roche AG |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
|
ES2594893T3
(es)
|
2009-12-16 |
2016-12-23 |
Abbvie Biotherapeutics Inc. |
Anticuerpos anti HER2 y sus usos
|
|
DK2536748T3
(da)
|
2010-02-18 |
2014-10-13 |
Genentech Inc |
Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
|
|
CN102167742B
(zh)
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗her2单克隆抗体、其制备方法及用途
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
WO2012075581A1
(en)
|
2010-12-06 |
2012-06-14 |
Ym Biosciences Inc. |
Antibodies selective for cells presenting erbb2 at high density
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
US20140363438A1
(en)
|
2011-08-17 |
2014-12-11 |
Genentech, Inc. |
Neuregulin antibodies and uses thereof
|
|
WO2013055874A2
(en)
|
2011-10-14 |
2013-04-18 |
Genentech, Inc. |
Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
|
|
WO2013063229A1
(en)
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
RU2014126098A
(ru)
|
2011-11-30 |
2016-01-27 |
Дженентек, Инк. |
МУТАЦИИ ErbB3 ПРИ РАКЕ
|
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
|
PT2802607T
(pt)
*
|
2012-01-13 |
2018-01-03 |
Univ Wuerzburg J Maximilians |
Complementação funcional bipartida induzida por duplo antigénio
|
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
|
KR101505157B1
(ko)
|
2012-05-08 |
2015-03-24 |
주식회사 종근당 |
항―ＥｒｂＢ２ 항체 변이체
|
|
WO2014052713A2
(en)
|
2012-09-27 |
2014-04-03 |
Massachusetts Institute Of Technology |
Her2-and vegf-a-binding proteins with enhanced stability
|
|
CN104837502B
(zh)
|
2012-10-12 |
2018-08-10 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
|
AU2013337926B2
(en)
|
2012-10-30 |
2017-12-21 |
Esperance Pharmaceuticals, Inc. |
Antibody/drug conjugates and methods of use
|
|
KR102291355B1
(ko)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
|
|
CA2905181C
(en)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
|
|
EP2983790A2
(en)
|
2013-04-09 |
2016-02-17 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
RU2019115089A
(ru)
|
2013-04-16 |
2019-06-11 |
Дженентек, Инк. |
Варианты пертузумаба и их аналитическая характеристика
|
|
WO2014182970A1
(en)
*
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
UA129760C2
(uk)
|
2013-12-17 |
2025-07-30 |
Дженентек, Інк. |
Анти-cd3 антитіло та спосіб його застосування
|
|
EP3327038B1
(en)
|
2013-12-20 |
2020-09-23 |
F. Hoffmann-La Roche AG |
Bispecific her2 antibodies and methods of use
|
|
WO2017019623A2
(en)
|
2015-07-26 |
2017-02-02 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
|
AU2015229583B2
(en)
|
2014-03-11 |
2020-07-09 |
Molecular Templates, Inc. |
Proteins comprising amino-terminal proximal Shiga toxin A Subunit effector regions and cell-targeting immunoglobulin-type binding regions
|
|
ES2723774T3
(es)
|
2014-03-11 |
2019-09-02 |
Molecular Templates Inc |
Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
|
|
MX2016012830A
(es)
*
|
2014-04-11 |
2017-01-05 |
Medimmune Llc |
Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
|
|
JP2017513901A
(ja)
|
2014-04-25 |
2017-06-01 |
ジェネンテック， インコーポレイテッド |
トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
KR101515535B1
(ko)
|
2015-01-28 |
2015-05-06 |
주식회사 종근당 |
항―ＥｒｂＢ２ 항체 변이체
|
|
CN105985435B
(zh)
|
2015-01-30 |
2019-10-15 |
嘉和生物药业有限公司 |
全人源her2抗体的突变抗体及其编码基因和应用
|
|
US11406715B2
(en)
|
2015-05-30 |
2022-08-09 |
Genentech, Inc. |
Methods of treating HER2-positive metastatic breast cancer
|
|
AU2016271124C1
(en)
|
2015-05-30 |
2020-05-14 |
Molecular Templates, Inc. |
De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
MX2017015618A
(es)
|
2015-06-03 |
2018-08-15 |
Boston Biomedical Inc |
Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer.
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
CN107787331B
(zh)
*
|
2015-06-17 |
2022-01-11 |
豪夫迈·罗氏有限公司 |
抗her2抗体和使用方法
|
|
TN2018000112A1
(en)
|
2015-10-29 |
2019-10-04 |
Novartis Ag |
Antibody conjugates comprising toll-like receptor agonist
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
|
CN109862919A
(zh)
|
2016-10-11 |
2019-06-07 |
免疫医疗有限公司 |
抗体-药物缀合物联合免疫介导的治疗剂
|
|
AU2017355432A1
(en)
|
2016-11-04 |
2019-05-16 |
F. Hoffmann-La Roche Ag |
Treatment of HER2-positive breast cancer
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
JP7106563B2
(ja)
|
2016-11-29 |
2022-07-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
ナフトフラン誘導体、その調製、および使用方法
|
|
AU2017387909A1
(en)
|
2016-12-28 |
2019-06-27 |
Genentech, Inc. |
Treatment of advanced HER2 expressing cancer
|
|
SG11201905622VA
(en)
|
2017-01-17 |
2019-08-27 |
Genentech Inc |
Subcutaneous her2 antibody formulations
|
|
EP3573648B1
(en)
|
2017-01-25 |
2023-11-22 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
|
US11077189B2
(en)
|
2017-03-02 |
2021-08-03 |
Genentech Inc. |
Adjuvant treatment of HER2-positive breast cancer
|
|
WO2018162376A1
(en)
*
|
2017-03-07 |
2018-09-13 |
F. Hoffmann-La Roche Ag |
Method for discovery of alternative antigen specific antibody variants
|
|
EP3615695A1
(en)
|
2017-04-24 |
2020-03-04 |
Genentech, Inc. |
Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
CA3062656A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
WO2019057772A1
(en)
|
2017-09-19 |
2019-03-28 |
Paul Scherrer Institut |
METHOD FOR CONJUGATING TRANSGLUTAMINASE AND BINDING SEQUENCE
|
|
JP7475275B2
(ja)
|
2018-02-08 |
2024-04-26 |
ジェネンテック， インコーポレイテッド |
二重特異性抗原結合分子及びその使用方法
|
|
AU2019257343A1
(en)
|
2018-04-17 |
2020-09-10 |
Molecular Templates, Inc. |
HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
EP3988574A4
(en)
*
|
2019-02-03 |
2022-10-12 |
Shanghai Bao Pharmaceuticals Co., Ltd. |
AGAINST HER2 BI-SPECIFIC ANTIBODIES AND THEIR USE
|
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
|
IL294829A
(en)
*
|
2020-01-23 |
2022-09-01 |
Bioatla Inc |
Conditionally active anti-HER2 antibodies, antibody fragments, their immunoconjugates and their uses
|
|
BR112022014568A2
(pt)
*
|
2020-01-23 |
2022-09-27 |
Exuma Biotech Corp |
Receptores de antígeno quiméricos contra her2 e métodos de uso dos mesmos
|
|
TWI867218B
(zh)
*
|
2020-04-30 |
2024-12-21 |
大陸商正大天晴藥業集團股份有限公司 |
靶向her2的抗原結合建構體及用途
|
|
AU2020456731A1
(en)
|
2020-06-29 |
2023-01-05 |
F. Hoffmann-La Roche Ag |
Pertuzumab plus trastuzumab fixed dose combination
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
CA3196218A1
(en)
|
2020-10-25 |
2022-04-28 |
Philipp SPYCHER |
Means and methods for producing antibody-linker conjugates
|
|
IL303350A
(en)
|
2020-12-04 |
2023-08-01 |
Macrogenics Inc |
Pharmaceutical compositions of a her2/neu antibody and use of the same
|
|
EP4281484B1
(en)
*
|
2021-01-22 |
2026-03-18 |
Hangzhou Baikai Biopharmaceutical Co., Ltd |
Anti-her-2/trop-2 constructs and uses thereof
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US12291575B2
(en)
|
2021-05-14 |
2025-05-06 |
Genentech, Inc. |
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
JP2025523630A
(ja)
|
2022-07-04 |
2025-07-23 |
ブイアイビー ブイゼットダブリュ |
血液－脳脊髄液関門通過抗体
|
|
CA3263050A1
(en)
|
2022-07-30 |
2024-02-08 |
Pinetree Therapeutics, Inc. |
Compositions for targeted lysosomal degradation and their methods of use
|
|
WO2024061224A1
(zh)
*
|
2022-09-20 |
2024-03-28 |
普米斯生物技术(珠海)有限公司 |
抗her2抗体及其用途
|
|
KR20250129814A
(ko)
|
2023-01-18 |
2025-08-29 |
타이리간드 바이오사이언스 (상하이) 리미티드 |
항체-약물 접합체 및 이의 용도
|
|
WO2024208816A1
(en)
|
2023-04-03 |
2024-10-10 |
Vib Vzw |
Blood-brain barrier crossing antibodies
|
|
WO2026032417A1
(zh)
*
|
2024-08-08 |
2026-02-12 |
石药集团巨石生物制药有限公司 |
Gspt1降解剂和含有gspt1降解剂的抗体偶联物及其用途
|